Capital BioVentures Launches ASCENT26: Accelerating Canada’s Next Therapeutic Breakthroughs

OTTAWA, Ontario — Capital BioVentures (CBV), a Canadian biotech accelerator supporting the growth of early-stage life sciences companies, today announced the launch of ASCENT26, the second cohort of its ASCENT program. Nine Canadian therapeutics companies have been selected to participate in the six-month virtual program, which provides targeted support to navigate critical development, corporate, and […]